Nonalcoholic Steatohepatitis (NASH) Protocol

NASH (Nonalcoholic Steatohepatitis) is a serious form of fatty liver disease where fat accumulation in the liver causes inflammation and liver cell damage—not from alcohol, but from metabolic dysfunction. It can progress to cirrhosis and liver failure. NASH is closely linked to obesity, insulin resistance, and metabolic syndrome. While weight loss through diet and exercise is the most effective treatment, certain supplements can support liver health and reduce inflammation.

IMPORTANT: NASH can be a serious progressive disease. Work with a hepatologist or gastroenterologist. Weight loss of 7-10% of body weight significantly improves NASH—this is the most important intervention.

•Vitamin E is the best-studied supplement for NASH. The landmark PIVENS trial showed that 800 IU daily improved liver inflammation and resolved NASH in significantly more patients than placebo. It works by reducing oxidative stress, which is a key driver of liver damage in NASH. It's now recommended in treatment guidelines for non-diabetic NASH patients.

•Milk Thistle (Silymarin) has been used for liver conditions for decades. It protects liver cells, increases glutathione (the liver's main antioxidant), reduces inflammation, and may help regenerate liver tissue. Studies show it can improve liver enzymes and may help with liver histology when combined with other treatments.

•Omega-3 Fatty Acids help reduce the fat accumulation in the liver and have anti-inflammatory effects. They improve triglyceride levels and may help reduce liver fat content. Higher doses (2-4g) are typically needed for liver benefits.

•Betaine is a methyl donor that supports the liver's methylation pathways. It helps process fats and may reduce the accumulation of fat in the liver. Studies show improvements in liver enzymes and histology, though large trials are needed.

•Probiotics/Synbiotics address the gut-liver axis—there's a strong connection between gut bacteria and liver health. Dysbiosis (imbalanced gut bacteria) contributes to liver inflammation through bacterial products crossing into the bloodstream. Probiotics can reduce this 'endotoxemia' and improve liver inflammation.

•L-Carnitine helps transport fatty acids into mitochondria for burning. By improving fatty acid oxidation in the liver, it may help reduce hepatic fat accumulation.

•Berberine activates AMPK (the body's 'metabolic master switch'), improving insulin sensitivity and reducing hepatic fat. It has benefits similar to the diabetes drug metformin and can improve liver enzymes in NAFLD/NASH.

•Curcumin has potent anti-inflammatory and antioxidant effects. Studies show it can reduce liver enzymes and may help with liver fat content.

Expected timeline: Liver enzyme improvements: 8-12 weeks. Histological improvements: 6-12 months of consistent treatment. Weight loss remains the cornerstone—aim for 1-2 lbs/week.

Clinical Perspective

NASH is defined histologically by hepatic steatosis (>5% hepatocytes), lobular inflammation, and hepatocyte ballooning, without significant alcohol use. It's the progressive form of NAFLD that can lead to fibrosis, cirrhosis, and hepatocellular carcinoma. Pathophysiology involves the 'multiple-hit' hypothesis: insulin resistance drives steatosis, then oxidative stress, lipotoxicity, ER stress, and gut-derived endotoxins cause inflammation and fibrosis. No FDA-approved pharmacotherapy exists; weight loss (≥7-10%) is first-line.

CRITICAL: NASH diagnosis requires liver biopsy or validated non-invasive markers. Exclude other liver diseases (viral hepatitis, autoimmune, alcohol). Fibrosis stage is the strongest predictor of outcomes—assess and monitor.

•Vitamin E (alpha-tocopherol) (A-grade): Lipid-soluble antioxidant that reduces oxidative stress. PIVENS trial (247 non-diabetic NASH patients): 800 IU/day for 96 weeks improved steatosis, inflammation, and NASH resolution vs placebo (43% vs 19%) but not fibrosis (PMID: 20427778). Meta-analysis confirms histological benefits (PMID: 28763256). AASLD guidelines recommend for biopsy-proven NASH in non-diabetics. Concerns about prostate cancer and all-cause mortality at high doses—discuss with patient. 800 IU/day; avoid in diabetics per original trial population.

•Milk Thistle (Silymarin) (B-grade): Flavonolignan complex with hepatoprotective, anti-inflammatory, and antifibrotic properties. Increases hepatocyte glutathione. Meta-analysis: reduces ALT/AST in NAFLD (PMID: 29080460). RCT: silymarin + vitamin E improved steatosis and liver enzymes (PMID: 28586419). 420-600mg/day silymarin. Phytosome formulations have enhanced bioavailability.

•Omega-3 Fatty Acids (B-grade): Reduce hepatic de novo lipogenesis (SREBP-1c inhibition), increase fatty acid oxidation (PPAR-α activation), and have anti-inflammatory effects. Cochrane review: reduce liver fat but no clear evidence for histological improvement (PMID: 26020006). May benefit hypertriglyceridemia component. 2-4g EPA/DHA daily; prescription formulations ensure purity/dose.

•Betaine (B-grade): Methyl donor (trimethylglycine) that supports hepatic methylation, including phosphatidylcholine synthesis. Pilot study: 10g BID for 1 year improved steatosis, inflammation, and fibrosis in some patients (PMID: 11283948). Limited larger trial data. 10-20g/day in divided doses. Well-tolerated.

•Probiotics/Synbiotics (B-grade): Address gut-liver axis dysfunction. Dysbiosis increases intestinal permeability and bacterial translocation (LPS → TLR4 → inflammation). Meta-analysis: probiotics reduce ALT, hepatic steatosis, and insulin resistance in NAFLD (PMID: 28371239). Multi-strain formulas with Lactobacillus, Bifidobacterium, and prebiotic fiber most studied.

•L-Carnitine (C-grade): Facilitates mitochondrial fatty acid oxidation. Systematic review: reduces ALT, AST, and may improve histology (PMID: 25732552). Smaller effect sizes than other interventions. 1-2g/day.

•Berberine (B-grade): Alkaloid that activates AMPK, inhibits PCSK9, improves insulin sensitivity. Meta-analysis: reduces ALT, triglycerides, and hepatic fat content (PMID: 26547628). Metabolic benefits similar to metformin. 500mg 2-3x/day. May interact with CYP3A4 substrates.

•Curcumin (B-grade): Anti-inflammatory (NF-κB inhibition), antioxidant (Nrf2 activation). Meta-analysis: reduces ALT, AST, and hepatic fat (PMID: 31123302). Bioavailability critical—use enhanced formulations. 500-1500mg/day.

Biomarker targets: ALT, AST, GGT (improvement suggests benefit), FibroScan/MRE for fibrosis staging, MRI-PDFF for steatosis quantification, lipid panel, HbA1c, HOMA-IR, liver biopsy if diagnosis uncertain or assessing treatment response.

Protocol notes: Weight loss ≥7-10% is the most effective intervention—improves all histological features including fibrosis. Mediterranean diet particularly beneficial. Exercise (150 min/week moderate intensity) improves NASH independent of weight loss. Metformin improves insulin resistance but doesn't improve histology. Pioglitazone improves histology but has weight gain and other side effects. GLP-1 agonists (semaglutide) show promise. Bariatric surgery highly effective for NASH with obesity. SGLT2 inhibitors being studied. Coffee consumption inversely associated with liver fibrosis. Avoid fructose-sweetened beverages. Statins are safe in NAFLD/NASH and often indicated for dyslipidemia. Vaccinate against hepatitis A/B. Screen for hepatocellular carcinoma if cirrhosis.

View All Protocols